POLARITYTE INC (PTE)
US7310942070 - Common Stock
Overall PTE gets a fundamental rating of 3 out of 10. We evaluated PTE against 587 industry peers in the Biotechnology industry. While PTE seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, PTE is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PTE had negative earnings in the past year.
PTE had a negative operating cash flow in the past year.
PTE had negative earnings in each of the past 5 years.
PTE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PTE has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTE has been increased compared to 1 year ago.
The number of shares outstanding for PTE has been increased compared to 5 years ago.
The debt/assets ratio for PTE has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -43.73, we must say that PTE is in the distress zone and has some risk of bankruptcy.
PTE has a Altman-Z score of -43.73. This is amonst the worse of the industry: PTE underperforms 91.49% of its industry peers.
PTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -43.73 |
ROIC/WACCN/A
WACC9.96%
2.3 Liquidity
PTE has a Current Ratio of 4.11. This indicates that PTE is financially healthy and has no problem in meeting its short term obligations.
PTE has a Current ratio of 4.11. This is comparable to the rest of the industry: PTE outperforms 43.02% of its industry peers.
A Quick Ratio of 4.11 indicates that PTE has no problem at all paying its short term obligations.
PTE has a Quick ratio (4.11) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.11 | ||
| Quick Ratio | 4.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 61.44% over the past year.
PTE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.66%.
PTE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -47.73% yearly.
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q74.22%
Revenue 1Y (TTM)-98.66%
Revenue growth 3Y-47.73%
Revenue growth 5YN/A
Revenue growth Q2Q-100%
3.2 Future
The Earnings Per Share is expected to grow by 28.11% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 176.69% on average over the next years. This is a very strong growth
EPS Next Y48.01%
EPS Next 2Y33.03%
EPS Next 3Y35.36%
EPS Next 5Y28.11%
Revenue Next Year-100%
Revenue Next 2Y179.39%
Revenue Next 3Y299.65%
Revenue Next 5Y176.69%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PTE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PTE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PTE's earnings are expected to grow with 35.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.03%
EPS Next 3Y35.36%
5. Dividend
5.1 Amount
No dividends for PTE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
POLARITYTE INC
NASDAQ:PTE (6/15/2023, 7:20:22 PM)
After market: 0.2249 -0.02 (-6.68%)0.241
0 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.11 | ||
| Quick Ratio | 4.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)61.44%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y48.01%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-98.66%
Revenue growth 3Y-47.73%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y